Detalles de la búsqueda
1.
Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Mov Disord
; 26(12): 2246-52, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21755537
2.
Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.
Anesthesiology
; 111(3): 616-24, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19672186
3.
Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.
Clin Neuropharmacol
; 41(2): 47-55, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29432286
4.
Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials.
Lancet
; 368(9539): 929-37, 2006 Sep 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-16962882
5.
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
J Neurol Sci
; 373: 116-123, 2017 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28131167
6.
Pharmacokinetics and pharmacodynamics of warfarin when coadministered with pentosan polysulfate sodium.
J Clin Pharmacol
; 45(8): 919-26, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16027402
7.
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
CNS Drugs
; 29(4): 341-50, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25895021
8.
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
J Parkinsons Dis
; 5(4): 837-45, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26444090
9.
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Mayo Clin Proc
; 78(6): 687-95, 2003 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-12934777
10.
Oxybutynin chloride: alterations in drug delivery and improved therapeutic index.
Expert Opin Pharmacother
; 3(4): 443-54, 2002 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-11934349
11.
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Parkinsonism Relat Disord
; 20(12): 1335-40, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25306200
12.
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Parkinsonism Relat Disord
; 20(2): 142-8, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24055014
13.
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Lancet Neurol
; 12(4): 346-56, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23485610
14.
A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.
Clin Pharmacokinet
; 52(2): 125-37, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23212610
15.
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
Int Urogynecol J Pelvic Floor Dysfunct
; 17(5): 502-11, 2006 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-16724169
Resultados
1 -
15
de 15
1
Próxima >
>>